| Campo DC | Valor | Idioma |
|---|
| dc.contributor.author | Almeida, José Roberto Fogaça de | - |
| dc.contributor.author | Santiago, Karla L. | - |
| dc.contributor.author | Kaihami, Gilberto Hideo | - |
| dc.contributor.author | Maranhão, Andrea Queiroz | - |
| dc.contributor.author | Brígido, Marcelo de Macedo | - |
| dc.contributor.author | Almeida, Sandro Rogério de | - |
| dc.date.accessioned | 2017-07-20T15:52:12Z | - |
| dc.date.available | 2017-07-20T15:52:12Z | - |
| dc.date.issued | 2017-03-03 | - |
| dc.identifier.citation | ALMEIDA, José Roberto Fogaça de et al. The efficacy of humanized antibody against the Sporothrix antigen, gp70, in promoting phagocytosis and reducing disease burden. Frontiers in Microbiology, v. 8, Article 345, 3 mar. 2017. Disponível em: <http://journal.frontiersin.org/article/10.3389/fmicb.2017.00345/full>. Acesso em: 27 jun. 2017. doi: http://journal.frontiersin.org/article/10.3389/fmicb.2017.00345/full. | pt_BR |
| dc.identifier.uri | http://repositorio.unb.br/handle/10482/23865 | - |
| dc.language.iso | Inglês | pt_BR |
| dc.publisher | Frontiers | pt_BR |
| dc.rights | Acesso Aberto | pt_BR |
| dc.title | The efficacy of humanized antibody against the Sporothrix antigen, gp70, in promoting phagocytosis and reducing disease burden | pt_BR |
| dc.type | Artigo | pt_BR |
| dc.subject.keyword | Micoses | pt_BR |
| dc.subject.keyword | Fungos | pt_BR |
| dc.subject.keyword | Anticorpos | pt_BR |
| dc.rights.license | Copyright © 2017 de Almeida, Santiago, Kaihami, Maranhão, de Macedo Brígido and de Almeida. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Fpnte: http://journal.frontiersin.org/article/10.3389/fmicb.2017.00345/full. Acesso em: 20 jul. 2017. | pt_BR |
| dc.identifier.doi | https://dx.doi.org/10.3389/fmicb.2017.00345 | pt_BR |
| dc.description.abstract1 | Sporotrichosis is a subcutaneous mycosis distributed worldwide and is frequently reported in countries with tropical climates, as Latin America countries. We previously demonstrated that mice with sporotrichosis produce specific antibodies against a 70-kDa fungal protein, indicating that specific antibodies against this molecule may help to control the sporotrichosis. IgG1 monoclonal antibody was generated, and called mAbP6E7, in mice against a 70-kDa glycoprotein (gp70) of S. schenckii. The mAbP6E7 showed prophylactic and therapeutic activity against sporotrichosis. However, this antibody has a murine origin, and this can generate an immune response when administered to humans, precluding its use for a prolonged time. For its possible use in the treatment of human sporotrichosis, we humanized the mAbP6E7 by genetic
engineering. Once expressed, the humanized antibodies had good stability and were able to bind to the 70-kDa cell wall antigens of Sporothrix schenckii and S. brasiliensis. The humanized P6E7 were able to opsonize S. schenckii yeasts, thus increasing the phagocytic index in human monocyte-derived macrophages. The treatment with humanized P6E7 decreased fungal burden in vivo. These data suggest that humanized P6E7 may have a therapeutic role in sporotrichosis. | pt_BR |
| Aparece nas coleções: | Artigos publicados em periódicos e afins
|
